Thermo Fisher Scientific Inc (TMO) to Post FY2017 Earnings of $9.33 Per Share, Leerink Swann Forecasts
Thermo Fisher Scientific Inc (NYSE:TMO) – Equities research analysts at Leerink Swann dropped their FY2017 earnings per share (EPS) estimates for Thermo Fisher Scientific in a research note issued on Monday. Leerink Swann analyst P. Souda now expects that the medical research company will earn $9.33 per share for the year, down from their previous estimate of $9.34. Leerink Swann currently has a “Outperform” rating and a $200.00 target price on the stock. Leerink Swann also issued estimates for Thermo Fisher Scientific’s Q1 2018 earnings at $2.36 EPS, Q2 2019 earnings at $2.82 EPS, Q3 2019 earnings at $2.83 EPS and FY2019 earnings at $11.24 EPS.
Several other research firms also recently commented on TMO. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $212.00 target price for the company in a research report on Thursday, September 21st. Cowen reissued an “outperform” rating and issued a $220.00 target price (up from $200.00) on shares of Thermo Fisher Scientific in a research report on Sunday, September 10th. Deutsche Bank set a $226.00 target price on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a research report on Thursday, October 26th. Barclays reissued an “overweight” rating and issued a $215.00 target price (up from $200.00) on shares of Thermo Fisher Scientific in a research report on Monday, September 25th. Finally, Goldman Sachs Group began coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, September 26th. They issued a “buy” rating and a $225.00 target price for the company. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $205.21.
Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 25th. The medical research company reported $2.31 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.24 by $0.07. The company had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $5.03 billion. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The company’s revenue for the quarter was up 13.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.03 earnings per share.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, January 15th. Investors of record on Friday, December 15th will be issued a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a dividend yield of 0.33%. The ex-dividend date of this dividend is Thursday, December 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.19%.
In related news, CEO Marc N. Casper sold 50,000 shares of the company’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $188.39, for a total transaction of $9,419,500.00. Following the completion of the sale, the chief executive officer now directly owns 252,577 shares of the company’s stock, valued at approximately $47,582,981.03. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.49% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Covington Capital Management raised its stake in Thermo Fisher Scientific by 0.9% during the 2nd quarter. Covington Capital Management now owns 2,144 shares of the medical research company’s stock valued at $374,000 after purchasing an additional 20 shares during the last quarter. Investment Centers of America Inc. raised its stake in Thermo Fisher Scientific by 1.6% during the 2nd quarter. Investment Centers of America Inc. now owns 1,317 shares of the medical research company’s stock valued at $230,000 after purchasing an additional 21 shares during the last quarter. Fort Washington Investment Advisors Inc. OH raised its stake in Thermo Fisher Scientific by 0.4% during the 2nd quarter. Fort Washington Investment Advisors Inc. OH now owns 6,250 shares of the medical research company’s stock valued at $1,090,000 after purchasing an additional 23 shares during the last quarter. Azimuth Capital Management LLC raised its stake in Thermo Fisher Scientific by 0.8% during the 1st quarter. Azimuth Capital Management LLC now owns 3,210 shares of the medical research company’s stock valued at $493,000 after purchasing an additional 25 shares during the last quarter. Finally, Bienville Capital Management LLC raised its stake in Thermo Fisher Scientific by 1.6% during the 2nd quarter. Bienville Capital Management LLC now owns 1,687 shares of the medical research company’s stock valued at $295,000 after purchasing an additional 27 shares during the last quarter. 86.16% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: This story was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/12/06/thermo-fisher-scientific-inc-tmo-to-post-fy2017-earnings-of-9-33-per-share-leerink-swann-forecasts.html.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.